

The acute management of central retinal artery occlusion (CRAO) has shifted from eye-care providers (eg, optometrists and ophthalmologists) to stroke neurologists, with emphasis on hyperacute management, expedited diagnostic tests, and aggressive secondary prevention.1,2 Revascularisation of the ischaemic retina with thrombolysis is supported by anecdotal cases, open-label studies, and meta-analyses of observational data, suggesting that intravenous thrombolysis is a low-risk therapy in patients with acute CRAO.
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet